Search

Your search keyword '"Greenwell, I Brian"' showing total 11 results
Start Over Author "Greenwell, I Brian"
11 results on '"Greenwell, I Brian"'

1. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma

Author

Sawalha, Yazeed, Goyal, Subir, Switchenko, Jeffrey M., Romancik, Jason T., Kamdar, Manali, Greenwell, I. Brian, Hess, Brian T., Isaac, Krista M., Portell, Craig A., Mejia Garcia, Alex, Goldsmith, Scott, Grover, Natalie S., Riedell, Peter A., Karmali, Reem, Burkart, Madelyn, Buege, Michael, Akhtar, Othman, Torka, Pallawi, Kumar, Anita, Hill, Brian T., Kahl, Brad S., and Cohen, Jonathon B.

Published
2023
Full Text
View/download PDF

3. PI3K Inhibitors: Understanding Toxicity Mechanisms and Management

Author

Greenwell, I. Brian, Ip, Andrew, and Cohen, Jonathon B.

Subjects
Phosphotransferases -- Health aspects, Enzyme inhibitors -- Health aspects, Lymphomas -- Development and progression -- Care and treatment, Toxicity, Drug approval, Skin, Tumors, Hypertension, Opportunistic infections, Phospholipids, Recurrence (Disease), Hyperglycemia, B cells, Health
Abstract

The phosphatidylinositol 3-kinase (PI3K) pathway has attracted immense interest as a therapeutic target for cancer treatment. Idelalisib was the first PI3K inhibitor approved by the US Food and Drug Administration and is utilized in the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. Copanlisib has subsequently been approved for relapsed follicular lymphoma in patients who have received at least two prior systemic therapies. There are multiple other PI3K agents currently in development; these target various combinations of PI3K isoforms. Despite the therapeutic benefit, there have been concerns about the severe and sometimes fatal adverse effects of this class of drug. Several side effects are unusual and have poorly understood mechanisms; these include autoimmune dysfunction, opportunistic infections, skin toxicity, hypertension, and hyperglycemia. An understanding of these unusual toxicities, as well as a good grasp of management principles, will be important as more PI3K inhibitors are approved and become incorporated into routine practice., Overview The phosphatidylinositol 3-kinase (PI3K) family consists of highly conserved enzymes that are a part of the intracellular PI3K/Akt/mammalian target of rapamycin (mTOR) signaling axis. This axis transmits cell surface [...]

Published
2017

6. Complex karyotype in mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy

Author

Greenwell, I Brian, Staton, Ashley D, Lee, Michael J, Switchenko, Jeffrey M, Saxe, Debra, Maly, Joseph J, Blum, Kristie A, Grover, Natalie S, Mathews, Stephanie, Gordon, Max J, Danilov, Alexey V, Epperla, Narendranath, Fenske, Timothy S, Hamadani, Mehdi, Park, Steven I, Flowers, Christopher R, and Cohen, Jonathon B

Subjects
Adult, Male, Karyotype, Lymphoma, Mantle-Cell, Risk Assessment, Transplantation, Autologous, Article, Predictive Value of Tests, Antineoplastic Combined Chemotherapy Protocols, Humans, Genetic Testing, Aged, Retrospective Studies, Aged, 80 and over, Chromosome Aberrations, Remission Induction, Hematopoietic Stem Cell Transplantation, Middle Aged, Prognosis, Combined Modality Therapy, Progression-Free Survival, United States, Ki-67 Antigen, Karyotyping, Female, Follow-Up Studies
Abstract

Risk stratification of newly diagnosed patients with mantle cell lymphoma (MCL) primarily is based on the MCL International Prognostic Index (MIPI) and Ki-67 proliferative index. Single-center studies have reported inferior outcomes in patients with a complex karyotype (CK), but this remains an area of controversy.The authors retrospectively reviewed 483 patients from 5 academic centers in the United States and described the effect of a CK on survival outcomes in individuals with MCL.A CK was found to be associated with inferior overall survival (OS) (4.5 vs 11.6 years; P.01) and progression-free survival (PFS) (1.9 vs 4.4 years; P.01). In patients who underwent high-intensity induction followed by autologous stem cell transplantation (ASCT) in first remission, a CK was associated with poor OS (5.1 vs 11.6 years; P = .04) and PFS (3.6 vs 7.8 years; P.01). Among patients with a CK, high-intensity induction had no effect on OS (4.5 vs 3.8 years; P = .77) nor PFS (2.3 vs 1.5 years; P = .46). Similarly, ASCT in first remission did not improve PFS (3.5 vs 1.2 years; P = .12) nor OS (5.1 vs 4.0 years; P = .27). On multivariable analyses with Ki-67 and MIPI, only CK was found to be predictive of OS (hazard ratio [HR], 1.98; 95% confidence interval [95% CI], 1.12-3.49 [P = .02]), whereas both CK (HR, 1.91; 95% CI, 1.17-3.12 [P = .01]) and Ki-6730% (HR, 1.86; 95% CI, 1.06-3.28 [P = .03]) were associated with inferior PFS. Multivariable analysis did not identify any specific cytogenetic abnormalities associated with inferior survival.CK appears to be independently associated with inferior outcomes in patients with MCL regardless of the intensity of induction therapy and receipt of ASCT. Cytogenetics should be incorporated into the workup of a new diagnosis of MCL and novel therapeutic approaches should be investigated for patients with CK. Cancer 2018;124:2306-15. © 2018 American Cancer Society.

Published
2018

8. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy

Author

Greenwell, I. Brian, primary, Staton, Ashley D., additional, Lee, Michael J., additional, Switchenko, Jeffrey M., additional, Saxe, Debra F., additional, Maly, Joseph J., additional, Blum, Kristie A., additional, Grover, Natalie S., additional, Mathews, Stephanie P., additional, Gordon, Max J., additional, Danilov, Alexey V., additional, Epperla, Narendranath, additional, Fenske, Timothy S., additional, Hamadani, Mehdi, additional, Park, Steven I., additional, Flowers, Christopher R., additional, and Cohen, Jonathon B., additional

Published
2018
Full Text
View/download PDF

9. Association of Complex Karyotype with Inferior Survival in Mantle Cell Lymphoma is Independent of Specific Cytogenetic Abnormalities

Author

Greenwell, I. Brian, primary, Staton, Ashley D., additional, Lee, Michael, additional, Switchenko, Jeffrey M., additional, Maly, Joseph, additional, Blum, Kristie, additional, Grover, Natalie, additional, Mathews, Stephanie, additional, Park, Steven, additional, Gordon, Max, additional, Danilov, Alexy, additional, Fenske, Timothy, additional, Epperla, Narendranath, additional, Hamadani, Mehdi, additional, Flowers, Christopher, additional, and Cohen, Jonathon, additional

Published
2017
Full Text
View/download PDF

10. Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma.

Author

Greenwell, I Brian, primary, Staton, Ashley Darnell, additional, Lee, Michael J, additional, Switchenko, Jeffrey M., additional, Maly, Joseph J., additional, Blum, Kristie A., additional, Grover, Natalie Sophia, additional, Mathews, Stephanie, additional, Park, Steven I., additional, Gordon, Max J, additional, Danilov, Alexey Valeryevich, additional, Flowers, Christopher, additional, and Cohen, Jonathon Brett, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results